PayPoint plc : Director/PDMR Shareholding 24 April

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
27
PayPoint plc : Director/PDMR Shareholding

24 April 2017

PayPoint plc ("the Company")

As a result of transactions on 21st April 2017 by the PayPoint plc Share Incentive Plan (a HM Revenue & Customs approved all employee share purchase plan), the executive directors and persons discharging management responsibility of the Company have the following interests as a result of their personal participation in the Plan:-

                                                               

      Partnership Shares Purchase Date: 21/04/2017 Share Price: £10.11 Matching Shares Award Date: 21/04/2017 Share Price: £10.11 Total number of Partnership, Matching and Dividend Shares held on 21/04/2017
Dominic Taylor 12 12 11,279
Tim Watkin-Rees 13 13 11,337
Jon Marchant 12 12 1,943
Susan Court 12 12 6,394
Katy Wilde 12 12 1,066
Lewis Alcraft 12 12 4,389
Rachel Kentleton 12 12 326

In accordance with the rules of the Plan the persons named above have been awarded the Matching Shares on the basis of one Matching Share for each Partnership Share. The beneficial ownership of the Matching Shares will pass to the persons listed above in three years time subject to continued employment and the retention of the underlying Partnership Shares.

The following notifications have been submitted to the FCA:

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Dominic Taylor
2. Reason for the notification
b) Position / status   Chief Executive
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.                                                             
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Timothy Watkin-Rees
2. Reason for the notification
b) Position / status   Business Development Director
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       13 £10.11                       13  
d) Aggregated information   Aggregated volume   Price     26   £262.86
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Jonathan Marchant
2. Reason for the notification
b) Position / status   Chief Information Officer
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Susan Court
2. Reason for the notification
b) Position / status   Head of Legal and Company Secretary
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Katy Wilde
2. Reason for the notification
b) Position / status   HR Director
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Lewis Alcraft
2. Reason for the notification
b) Position / status   Commercial Director
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London

Director/PDMR shareholding - Transaction notification

1. Details of PDMR / person closely associated with them ('PCA')
a) Name   Rachel Kentleton
2. Reason for the notification
b) Position / status   Finance Director
c) Initial notification/amendment   Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint plc  
b) LEI code 5493004YKWI8U0GDD138  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument   Identification code Ordinary shares of 1/3p each   GB00B02QND93  
b) Nature of the transaction   Participation in the PayPoint Share Incentive Plan whereby purchase of shares are self-funded under the plan and matching shares are awarded for each share purchased.  
c) Price(s) and volume(s)   Price(s)                     Volumes £10.11                       12 £10.11                       12  
d) Aggregated information   Aggregated volume   Price     24   £242.64
e) Date of the transaction   2017-04-21
f) Place of the transaction   London
Name of officer of issuer responsible for making notification: Susan Court   Date of notification: 24 April 2017  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading